Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0X9RG
|
||||
Former ID |
DAP000214
|
||||
Drug Name |
Butorphanol
|
||||
Synonyms |
Beforal; Butorfanol; Butorphanolum; Moradol; Stadol; Butorphanol tartrate; BC-2627; Beforal (TN); Butorfanol [INN-Spanish]; Butorphanolum [INN-Latin]; L-BC 2627; Moradol (TN); Butorphanol (USAN/INN); Butorphanol [USAN:BAN:INN]; Levo-BC-2627; (-)-17-(Cyclobutylmethyl)morphinan-3,14-diol; (-)-N-cyclobutylmethyl-3,14-dihydroxymorphinan; (-)-butorphanol; 17-(CYCLOBUTYLMETHYL)MORPHINAN-3,14-DIOL
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Analgesics
|
||||
Company |
Apotex Inc
|
||||
Structure |
Download2D MOL |
||||
Formula |
C21H29NO2
|
||||
InChI |
InChI=1S/C21H29NO2/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15/h6-7,13,15,19,23-24H,1-5,8-12,14H2/t19-,20+,21-/m1/s1
|
||||
InChIKey |
IFKLAQQSCNILHL-QHAWAJNXSA-N
|
||||
CAS Number |
CAS 58786-99-5
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
9081, 14801765, 14875085, 17397351, 32960763, 48415674, 49992740, 50631323, 57371628, 92729940, 93166707, 103205944, 104098285, 126666040, 134224509, 135000864, 136280316, 137005108, 139157626, 160963956, 163074576, 164837504, 175265477, 179150474, 198993287, 223365926, 223670035, 224782792, 226395864, 241079392, 250136746, 252346885
|
||||
SuperDrug ATC ID |
N02AF01
|
||||
SuperDrug CAS ID |
cas=042408822
|
||||
Target and Pathway | |||||
Target(s) | Delta-type opioid receptor | Target Info | Agonist | [536098] | |
References | |||||
Ref 538290 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075046. | ||||
Ref 542581 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7591). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.